healthcare stocks

Three healthcare stocks—Pfizer (6.5% yield), Medtronic (3.6% yield with 48-year dividend streak), and Omega Healthcare (5.8% yield)—offer retirees attractive income streams amid aging demographics.

Eli Lilly eyes $2 trillion valuation from weight-loss drugs, Alzheimer's breakthroughs, and AI-powered R&D following recent market pullback.

CVS Health stock jumped 6.09% to 52-week high after beating Q1 earnings expectations and raising 2026 guidance, driven by improved medical cost ratios.

Record earnings beats and 27% growth challenge the 'Sell in May' strategy in 2026, with selective stock opportunities offering upside potential despite geopolitical risks.

Intuitive Surgical and Vertex Pharmaceuticals trade near $425-460, offering investors two shares with $1,000 despite recent sector headwinds and competitive pressures.

Healthcare stocks $JNJ, $VRTX, and $UNH offer compelling long-term wealth-building opportunities through strong fundamentals, dividend history, and operational improvements.

Three healthcare stocks offer yields above 6%: Perrigo (9.6%), Healthpeak (7.1%), and Medical Properties Trust (6.8%), but each faces distinct challenges.

Eli Lilly shows 43% revenue growth and 51% EPS growth, backed by weight-loss drug leadership and $7B cancer acquisition. Forward P/E of 40 remains below historical average.

Eli Lilly, Vertex Pharmaceuticals, and Intuitive Surgical possess durable competitive moats—patent protection and market dominance—supporting sustained earnings growth through the 2030s.

Small-cap biotech like CTMX offers explosive growth potential but carries significant risk; megacap pharma like JNJ provides stability and dividends with moderate returns.

Abbott offers diversified healthcare exposure with dividend income; Dexcom provides pure CGM growth but faces GLP-1 drug competition and concentration risk.

Market volatility has depressed healthcare valuations. Intuitive Surgical and Abbott Laboratories now trade at attractive multiples, offering long-term investment opportunities.

BDX offers 2.7% dividend yield, 50+ years of annual growth, and valuation discount amid healthcare sector headwinds.

CVS Health gains $13B from favorable Medicare payment decision. Stock trades at 11x forward earnings versus peers at 15-20x, suggesting $90-$100 upside potential.

BDX and ISRG emerge as defensive healthcare plays during market downturns, offering dividend stability and surgical innovation leadership respectively.

CVS Health navigates regulatory challenges while positive developments emerge, raising questions about dividend stock valuation amid industry pressures.

Contrarian investors target beaten-down financials, healthcare, and software sectors while cautioning against momentum-driven energy stock rallies despite long-term fundamentals.

Schwab's dividend ETF ($SCHD) reconstitutes holdings, replacing energy stocks with healthcare leaders. Offers 3.5% yield, triple S&P 500 average.

$100 invested in $CVS five years ago grew to $108.11 (1.6% annually), trailing $SPX significantly while offering 3.62% dividend yield.

Tech stocks tumble toward correction as investors shift to defensive healthcare dividends. AbbVie and Amgen offer stability through economic uncertainty.